---

Disclaimer: This information is intended for educational purposes and as a comprehensive clinical reference for healthcare professionals. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider in the context of the individual patient's circumstances, medical history, and current clinical presentation. Adherence to local institutional guidelines and current best practices is essential. Dosages, criteria, and guidelines may change, and clinicians are responsible for verifying the most current information.

---

Dupuytren's Contracture

Overview

• Definition: Dupuytren's contracture is a progressive fibroproliferative disorder affecting the palmar and digital fascia of the hand, characterized by the formation of nodules and cords that can lead to fixed flexion deformities of the fingers, primarily at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints. It is a benign condition but can significantly impair hand function.
• Epidemiology:
  • Prevalence: Varies geographically, with the highest prevalence in populations of Northern European (Celtic) descent, particularly in Scandinavia, the UK, and Ireland.
  • Sex: Males are affected more frequently and often more severely than females, with a male-to-female ratio estimated at 10:1.
  • Age: Typically presents in individuals over 50 years of age, with incidence increasing with age. Early onset (before age 50) is associated with more aggressive disease and higher recurrence rates.
  • Associated Conditions: Increased prevalence in individuals with diabetes mellitus, epilepsy (especially those on phenobarbital), chronic alcohol abuse, and smoking. It can also be associated with other fibromatoses such as Ledderhose disease (plantar fibromatosis) and Peyronie's disease (penile fibromatosis), and Garrod's pads (knuckle pads).
• Classification: There is no universally accepted formal classification system for Dupuytren's disease based on etiology or distinct types. However, it can be categorized by:
  • Severity: Based on the degree of contracture (e.g., using goniometric measurements of MCP and PIP joint angles), typically assessed by the total passive extension deficit (TPED).
  • Presence of Nodules/Cords: Early stage (nodules only) vs. advanced stage (contracting cords).
  • Associated Fibromatoses: Palmar (Dupuytren's), Plantar (Ledderhose), Penile (Peyronie's), Knuckle pads (Garrod's).
  • Recurrence: Primary vs. recurrent disease.

Pathophysiology

• Mechanism: The exact etiology remains unknown, but it is understood as a benign fibroproliferative disorder involving an abnormal wound healing process within the palmar fascia.
  • Myofibroblast Transformation: The key cellular event is the differentiation and proliferation of fibroblasts into myofibroblasts. These cells possess features of both fibroblasts (collagen production) and smooth muscle cells (contractile properties).
  • Collagen Deposition: Myofibroblasts produce excessive amounts of extracellular matrix, primarily collagen type III (rather than type I), leading to the formation of dense, non-compliant nodules and longitudinal cords.
  • Contraction: The contractile properties of myofibroblasts, coupled with the dense collagenous matrix, cause the shortening and thickening of the fascial structures, resulting in fixed flexion deformities of the affected digits.
  • Three Phases:
    1. Proliferative Phase: Characterized by increased cellularity, particularly fibroblasts and myofibroblasts, and abundant collagen type III deposition. Nodules form.
    2. Involutional Phase: Myofibroblasts align themselves along lines of tension, forming cords as they contract, causing the finger to flex.
    3. Residual Phase: Avascular, acellular collagenous cord remains, representing the fixed contracture.
  • Genetic Predisposition: Strong genetic component, with identified susceptibility loci, notably on chromosome 16q and 10q. It is thought to be an autosomal dominant trait with variable penetrance.
• Risk Factors:
  • Genetic: Family history of Dupuytren's contracture, Northern European ancestry.
  • Age: Increased incidence with advancing age (>50 years).
  • Sex: Male gender.
  • Medical Conditions:
    • Diabetes Mellitus: Associated with a higher incidence, typically affecting the thumb and index finger more, and often presenting as a diffuse disease.
    • Epilepsy: Particularly in patients treated with phenobarbital, though the link may be to the disease itself rather than the medication.
    • HIV/AIDS: Increased risk, often with more aggressive presentations.
  • Lifestyle:
    • Alcohol Abuse: Strong association, though the mechanism is unclear (possibly related to liver dysfunction or direct toxic effects).
    • Smoking: Dose-dependent relationship, potentially due to microvascular ischemia or oxidative stress.
  • Trauma: While historically considered a risk factor, the role of acute or repetitive hand trauma is controversial and not definitively proven as a primary cause, though it may accelerate progression in predisposed individuals.
• Protective Factors: No definitive protective factors have been identified.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Nodules: Firm, painless subcutaneous nodules usually found in the palmar fascia, most commonly at the base of the ring and little fingers. These are often the first sign.
  • Cords: Longitudinal fibrous cords extending from the palm into the fingers, representing thickened and contracted fascial bands. These cords can be palpable and visible.
  • Fixed Flexion Contracture: Inability to fully extend the affected finger(s), most commonly the ring and little fingers, followed by the middle finger, thumb, and index finger. The contracture can affect the MCP and/or PIP joints.
  • Painless: Typically, Dupuytren's contracture itself is painless. Pain, if present, should prompt consideration of other differential diagnoses or associated conditions.
• Early Signs:
  • Small, firm, non-tender nodules in the palm.
  • Skin pitting or tethering in the palm (due to the fascia pulling on the overlying skin).
  • Subtle loss of full finger extension, often noticed inadvertently (e.g., difficulty placing hand flat on a table).
• Advanced Signs:
  • Significant fixed flexion contracture of one or more digits, severely limiting hand function.
  • Skin maceration, hygiene issues, or difficulty with gripping due to severe contracture.
  • Development of contractures in multiple digits or in the thumb.
  • Associated fibromatoses (Ledderhose, Peyronie's, Garrod's pads).
• Atypical Presentations:
  • Unusual digits affected first (e.g., thumb or index finger).
  • Rapid progression of contracture.
  • Diffuse palmar involvement without discrete cords.
  • Significant pain (rare, but can occur with rapidly expanding nodules or nerve compression, though this is uncommon).
  • Very early onset (e.g., in childhood, which is exceedingly rare and often severe).

Physical Examination

• Inspection:
  • Observe the resting posture of the hand.
  • Identify palmar nodules and visible cords.
  • Note skin pitting, puckering, or tethering over the nodules/cords.
  • Assess for fixed flexion deformities of the MCP and PIP joints.
  • Examine for knuckle pads (Garrod's pads) over the dorsal aspect of the PIP joints.
  • Inspect for skin integrity, especially in severe contractures, where skin maceration may occur.
• Palpation:
  • Palpate the palm and digits for firm, non-tender nodules and longitudinal cords.
  • Assess the pliability of the skin and underlying tissues.
  • Differentiate between skin involvement and underlying fascial involvement.
  • Evaluate the range of motion of each digit, specifically measuring the passive extension deficit at the MCP and PIP joints using a goniometer.
• Special Tests:
  • Hueston's Table Top Test: The patient attempts to place the palm flat on a table. An inability to do so indicates a significant flexion contracture (typically >30° at the MCP joint or any PIP contracture) and often suggests the need for intervention. This is a practical, quick screening tool for functional impairment.
  • Measurement of Contracture: Using a goniometer, measure the passive extension deficit for each affected MCP and PIP joint. The sum of these deficits is the Total Passive Extension Deficit (TPED), which is a key metric for surgical planning and assessing severity.
  • Neurovascular Assessment: While less commonly affected by Dupuytren's itself, assess sensation and circulation to rule out other conditions or as part of a pre-operative evaluation, especially with severe or long-standing contractures.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression: When did you first notice changes in your hand? How quickly has it progressed? Has it been intermittent or continuous?
  • Affected Digits: Which fingers are involved? Has it spread to other fingers or the other hand?
  • Symptoms: Is there any pain, tenderness, or itching associated with the nodules/cords? (Typically, Dupuytren's is painless).
  • Functional Impact: How does the contracture affect daily activities (e.g., washing face, putting on gloves, shaking hands, typing, grasping large objects, putting hands in pockets)? This is crucial for determining the need for intervention.
  • Family History: Is there a family history of Dupuytren's or similar conditions?
  • Medical History: Any history of diabetes, epilepsy, liver disease? Current medications (e.g., phenobarbital)?
  • Social History: Alcohol consumption, smoking status.
  • Prior Trauma/Surgery: Any history of hand injury or previous hand surgery?
• Red Flags:
  • Significant Pain: While mild discomfort can occur, severe or rapidly increasing pain is unusual for Dupuytren's and warrants investigation for other causes (e.g., ganglion, tumor, inflammatory conditions).
  • Acute Onset/Rapid Progression: Though Dupuytren's can progress, very rapid development might prompt consideration of other fibromatoses or inflammatory processes.
  • Infection Signs: Erythema, warmth, pus – suggest a separate infectious process.
  • Numbness/Tingling: Suggests nerve compression, which is not a typical direct feature of Dupuytren's but can occur coincidentally (e.g., carpal tunnel syndrome).

Laboratory Tests

• First-Line: No laboratory tests are routinely required for the diagnosis of Dupuytren's contracture, as it is primarily a clinical diagnosis.
• Confirmatory: N/A.
• Monitoring: N/A. (However, if associated systemic conditions like diabetes or liver disease are suspected, relevant tests may be performed for those conditions, not for Dupuytren's itself).

Imaging

• Recommended: Imaging is generally not required for the routine diagnosis of Dupuytren's contracture, as it is a clinical diagnosis based on history and physical examination.
• Advanced: Imaging may be considered in specific circumstances:
  • Ultrasound: Can be used to confirm the diagnosis, differentiate Dupuytren's cords/nodules from other soft tissue masses (e.g., ganglion cysts, lipomas, foreign bodies, tumors), and delineate the extent and depth of the disease, especially in complex or recurrent cases. It can visualize the fascio-dermal connection and the relationship of cords to neurovascular bundles.
  • Magnetic Resonance Imaging (MRI): Reserved for highly complex cases, atypical presentations, or when there is suspicion of other underlying pathology (e.g., tumor, inflammatory processes, nerve involvement). MRI provides detailed soft tissue resolution, which can aid in surgical planning, particularly in recurrent or extensive disease, but is not cost-effective for routine diagnosis.

Management

Acute Management

Dupuytren's contracture is a chronic, progressive condition and does not typically require acute or emergency management. Interventions are generally elective and planned. - Immediate: N/A - Stabilization: N/A - Emergency: N/A

Chronic Management

Management depends on the severity of the contracture, the rate of progression, the presence of functional impairment, and patient preferences. - Pharmacological: * Collagenase Clostridium Histolyticum (CCH) (e.g., Xiaflex, Xiapex): * Mechanism: A purified enzyme blend that selectively hydrolyzes collagen in the Dupuytren's cord, weakening it sufficiently to allow for rupture and manual extension. * Indications: Adults with a palpable Dupuytren's cord and a fixed flexion contracture of an MCP or PIP joint. Less effective for PIP joint contractures, very thin cords, or diffuse disease. * Dosage & Administration: 0.58 mg per cord, injected directly into the Dupuytren's cord(s). Up to two joints can be treated in one hand at a single visit. After 24-72 hours, a finger extension procedure is performed by the clinician to rupture the cord. * Contraindications: Known hypersensitivity to CCH or collagen, presence of a cord in the thumb or index finger with skin bridging to the neurovascular bundle (due to higher risk of nerve/vessel injury). * Side Effects: Common local reactions include edema, ecchymosis, injection site pain, skin laceration/tear (often during manipulation), lymphadenopathy. Rare but serious: tendon rupture, nerve injury, allergic reactions. * Corticosteroid Injections: * Mechanism: Anti-inflammatory effects. * Indications: May provide temporary relief for painful or rapidly enlarging Dupuytren's nodules in the early proliferative phase. They do not treat contractures or prevent progression. * Efficacy: Limited evidence for long-term benefit; not a primary treatment for contracture. * Dimethyl Sulfoxide (DMSO): * Mechanism: Topical anti-inflammatory and collagen-modulating properties. * Efficacy: While some historical interest existed, there is insufficient evidence to support its use in routine clinical practice for Dupuytren's. - Non-pharmacological: * Observation ("Wait and Watch"): * Indications: Mild disease (e.g., nodules only, MCP contracture <30°, no significant PIP involvement, negative Hueston's table top test, no functional impairment). * Rationale: As the condition is benign and often progresses slowly, intervention is delayed until functional deficits arise. * Radiation Therapy (RT): * Mechanism: Low-dose radiation targets the proliferating fibroblasts and myofibroblasts, inhibiting their activity. * Indications: Primarily for early-stage disease (nodules, mild contractures <10-20° total deficit, or rapidly progressing disease) and for early recurrence. It is a prophylactic measure, aiming to prevent or slow progression, rather than correcting existing contracture. * Dose: Typically 30 Gy in 5 fractions over 5 days, or 21 Gy in 7 fractions over 7 days, repeated after 3 months if needed. * Efficacy: Evidence suggests it can halt or slow progression in early stages, with good long-term control rates reported in some studies. * Hand Therapy and Splinting: * Role: Primarily adjunctive, post-intervention. Not effective in reversing established contracture. * Post-Intervention: Critical for maintaining extension, improving range of motion, and minimizing stiffness after collagenase injection, needle aponeurotomy, or surgery. * Splinting: Static or dynamic splinting may be used post-intervention to maintain extension, particularly at the PIP joint. The evidence for long-term benefits in preventing recurrence is mixed and not definitive.

• Monitoring:
  • Regular clinical follow-up (e.g., every 6-12 months for observation) to assess contracture progression, measure joint angles (goniometry), and evaluate functional impact.
  • Post-intervention, monitor for signs of recurrence or complications.

Treatment Algorithms

The choice of intervention is highly individualized, depending on disease severity, functional impact, patient comorbidities, and surgeon expertise. Key thresholds for intervention include a positive Hueston's table top test, an MCP contracture of ≥30°, or any PIP contracture.

• First-Line:
  • Stage 0/1 (Nodules only, no significant contracture, no functional impairment):
    • Observation: Regular monitoring.
    • Radiation Therapy: Consider for rapidly progressing or painful nodules, or mild contractures (<20°), particularly in younger patients.
  • Stage 2/3 (MCP contracture ≥30° or any PIP contracture with functional impairment):
    • Percutaneous Needle Aponeurotomy (NA):
      • Mechanism: A minimally invasive procedure where a sharp needle (e.g., 20-gauge) is used to perforate and disrupt the Dupuytren's cord in multiple places through the skin, followed by manual manipulation to rupture the cord.
      • Indications: Well-defined, palpable cords causing MCP or PIP joint contracture (though less effective for PIP). Advantages include minimal invasiveness, local anesthesia, and quick recovery.
      • Limitations: Higher recurrence rates than surgery, risk of nerve/vessel injury (especially near PIP joints). Not suitable for diffuse disease or skin involvement.
    • Collagenase Clostridium Histolyticum (CCH): (See Pharmacological section for details).
      • Indications: Similar to NA – for distinct, palpable cords causing MCP or PIP joint contracture. Less invasive than surgery, but involves two visits (injection then manipulation).
      • Limitations: Cost, risk of local skin reactions, less effective for PIP joints.
    • Limited (or Selective) Fasciectomy:
      • Mechanism: Open surgical excision of the diseased palmar and digital fascia, preserving healthy tissue.
      • Indications: Gold standard for moderate to severe contractures, complex disease patterns, multiple finger involvement, PIP joint contractures, or recurrent disease where less invasive options are unsuitable. Also preferred if there is significant skin involvement.
      • Advantages: Lower recurrence rates compared to NA/CCH, allows for direct visualization of neurovascular structures.
      • Limitations: More invasive, longer recovery, general anesthesia often required, higher risk of surgical complications (infection, stiffness, wound healing issues).
• Second-Line:
  • If a less invasive method (NA or CCH) fails or is unsuitable for primary treatment:
    • Consider Limited Fasciectomy.
    • For severe PIP joint contractures or very extensive disease, Dermofasciectomy (excision of diseased fascia along with overlying skin and subsequent skin grafting) may be considered, particularly in patients with aggressive disease or high risk of recurrence.
    • Total Fasciectomy: Rarely performed due to higher morbidity and no clear advantage over limited fasciectomy.
• Refractory Cases:
  • Recurrent Disease: Management depends on the pattern and severity of recurrence. Options include repeat NA, CCH, limited fasciectomy, or dermofasciectomy. Radiation therapy may also be considered for early recurrence.
  • Severe, Long-standing Contractures: May require more extensive surgical procedures, including capsulotomy, joint release, skin grafting, or staged reconstruction. In rare, debilitating, and recalcitrant cases, amputation of the severely contracted digit may be considered as a last resort to improve overall hand function.

Complications

• Common:
  • Recurrence: The most common long-term complication, occurring in 20-80% of patients depending on the treatment method, disease severity, and patient factors (e.g., age of onset, family history, associated fibromatoses).
  • Stiffness/Reduced Range of Motion: Particularly after surgery, but also with NA and CCH. Hand therapy is crucial to mitigate this.
  • Pain and Swelling: Localized pain, tenderness, and swelling are common post-procedure.
  • Skin Complications: Skin tearing (especially with CCH and NA during manipulation), wound healing issues, hematoma, infection (less common with NA/CCH than surgery).
  • Pillar Pain: Pain at the base of the thumb and little finger following surgical incision.
• Serious:
  • Nerve Injury: Accidental transection or bruising of digital nerves (sensory loss, dysesthesia). Higher risk with NA/CCH near neurovascular bundles and in recurrent surgery due to distorted anatomy.
  • Vascular Injury: Damage to digital arteries, potentially leading to ischemia or vascular compromise.
  • Tendon Rupture: A rare but significant complication, particularly with CCH if injected into a tendon.
  • Complex Regional Pain Syndrome (CRPS): A rare but severe post-operative complication characterized by disproportionate pain, swelling, and autonomic dysfunction.
  • Infection: While less common, can occur after any invasive procedure.
  • Anesthesia Risks: Associated with surgical interventions requiring regional or general anesthesia.
• Long-term:
  • Persistent Contracture: Incomplete correction of the deformity.
  • Functional Limitations: Despite intervention, some degree of functional limitation may persist, especially with severe or recurrent disease.
  • Scarring: Visible and sometimes tender scarring, particularly after open surgery.
  • Need for Re-intervention: Due to recurrence or persistent contracture.

Prognosis

• Factors:
  • Genetics and Predisposition: Strong family history, Northern European ancestry, male sex, and early age of onset (before 50) are associated with more aggressive disease and higher recurrence rates.
  • Disease Severity: Extensive disease (multiple digits, thumb involvement), involvement of the PIP joints, and severe initial contracture lead to poorer outcomes and higher recurrence.
  • Associated Fibromatoses: Concurrent Ledderhose disease, Peyronie's disease, or Garrod's pads indicate a more generalized fibromatosis diathesis and a higher risk of recurrence.
  • Comorbidities: Diabetes, alcohol abuse, and smoking are associated with more severe disease and increased recurrence.
  • Treatment Method: While all methods aim to correct contracture, recurrence rates vary (e.g., generally lower with open fasciectomy compared to NA or CCH, but with higher initial morbidity). PIP joint contractures are notoriously difficult to fully correct and have higher recurrence rates regardless of treatment.
  • Post-Procedural Adherence: Compliance with hand therapy and splinting (if prescribed) can influence functional outcome.
• Survival: Dupuytren's contracture itself has no direct impact on patient survival.
• Quality of Life: Can significantly impair hand function, affecting activities of daily living, hobbies, and professional tasks, thereby reducing overall quality of life. Successful intervention aims to improve hand function and quality of life, but recurrence can again diminish these gains.

Prevention

• Primary: No proven methods to prevent the initial onset of Dupuytren's contracture. Due to its strong genetic component, primary prevention is challenging. Avoiding known risk factors like excessive alcohol consumption and smoking may theoretically reduce the risk or severity, but this is not definitively proven for primary prevention.
• Secondary: Early detection of nodules and cords, even without significant contracture, may allow for consideration of treatments like radiation therapy which aim to slow or halt disease progression before severe contractures develop. Regular self-examination of the hands is advisable for individuals with a family history or other risk factors.
• Tertiary: Focused on preventing complications and minimizing recurrence after intervention.
  • Post-Intervention Hand Therapy: Essential for maintaining range of motion, reducing stiffness, and strengthening the hand.
  • Splinting: Often used post-intervention to maintain digit extension, especially at the PIP joint, though evidence for its long-term impact on recurrence rates is mixed.
  • Regular Follow-up: Monitoring for signs of recurrence allows for timely re-intervention if necessary, potentially preventing the development of severe, recalcitrant contractures.
  • Management of Comorbidities: Optimizing control of diabetes, smoking cessation, and moderation of alcohol intake may help reduce the risk of recurrence and complications.

Special Populations

• Pediatric: Exceedingly rare. If present in childhood, Dupuytren's contracture tends to be aggressive, severe, and rapidly progressive. Other causes of congenital or acquired contractures should be ruled out. Management is challenging, and surgical intervention, often with dermofasciectomy, may be necessary but can be difficult due to small anatomy and potential for growth issues.
• Geriatric: More prevalent in older adults. Comorbidities (e.g., cardiovascular disease, diabetes, anticoagulation) may influence treatment choice, favoring less invasive options or local anesthesia. Functional goals may differ for elderly patients (e.g., maintaining basic hygiene vs. fine motor skills). Anesthesia risks need careful consideration for open surgery.
• Pregnancy: Dupuytren's contracture is an elective condition. Treatment is generally deferred until after pregnancy and lactation due to the lack of safety data for CCH and radiation therapy during pregnancy, and the potential risks of anesthesia for surgery.
• Comorbidities:
  • Diabetes Mellitus: Patients with diabetes have a higher prevalence of Dupuytren's, often presenting with diffuse involvement and affecting the thumb and index finger more frequently. They may also have an increased risk of wound healing complications and infection post-surgery.
  • Epilepsy: Increased incidence, especially in those on phenobarbital. No specific management modifications related to epilepsy itself, but overall health and medication interactions need to be considered.
  • Peripheral Vascular Disease: May increase risks of wound healing problems and ischemia, requiring careful pre-operative assessment.
  • Autoimmune/Connective Tissue Disorders: May present with hand contractures; careful differentiation from Dupuytren's is necessary.

Clinical Pearls

• Diagnostic:
  • Pain is the Exception: Dupuytren's is typically painless. If a patient reports significant pain, consider other diagnoses (e.g., ganglion, tumor, inflammatory conditions).
  • Hueston's Table Top Test: A simple, effective screening tool. If positive, intervention is often indicated due to functional impairment.
  • Systemic Examination: Always examine the contralateral hand, feet (Ledderhose disease), and inquire about penile fibromatosis (Peyronie's disease) and knuckle pads (Garrod's pads), as these indicate a more generalized diathesis.
  • Clinical Diagnosis: Emphasize that imaging is rarely needed for diagnosis and primarily aids in complex surgical planning or to rule out other pathology.
• Treatment:
  • Function over Appearance: The primary goal of intervention is to restore hand function and reduce contracture-related impairment, not cosmetic correction.
  • PIP Joints are Challenging: Contractures at the PIP joint are notoriously difficult to fully correct and have higher recurrence rates compared to MCP joint contractures, regardless of the treatment method. Manage patient expectations accordingly.
  • Recurrence is Common: Educate patients about the high likelihood of recurrence with any treatment method. This is a progressive disease, not a curable one.
  • Individualized Approach: No "one size fits all" treatment. The best approach depends on the patient's specific contracture, comorbidities, functional demands, and preferences. Discuss all viable options.
• Pitfalls:
  • Operating Too Early: Intervening before significant functional impairment or contracture (e.g., >30° MCP contracture or any PIP contracture) may lead to unnecessary complications without substantial benefit. "Wait and watch" is appropriate for mild disease.
  • Operating Too Late: Delaying intervention for very severe, long-standing contractures can result in incomplete correction and poorer functional outcomes, as joint changes and skin shortening become fixed.
  • Ignoring Comorbidities: Failure to account for conditions like diabetes or anticoagulation can lead to increased complications.
  • Inadequate Patient Education: Not fully informing patients about the chronic nature of the disease, the potential for recurrence, and the importance of post-procedure therapy can lead to dissatisfaction.
  • Misinterpreting Pain: Attributing all hand pain to Dupuytren's, potentially missing other treatable conditions.

Recent Updates

• Guidelines: Recent guidelines, such as those from the British Society for Surgery of the Hand (BSSH), emphasize a shared decision-making approach, considering patient preferences alongside objective measures of contracture and functional impairment. There's a growing acceptance of less invasive treatments (NA, CCH) as first-line options for appropriate patients, especially for MCP joint contractures.
• Evidence:
  • Comparative Effectiveness: Ongoing studies continue to refine the indications for NA, CCH, and open surgery, comparing long-term efficacy, recurrence rates, and complication profiles. While open fasciectomy often has lower recurrence, NA and CCH offer quicker recovery and fewer initial complications.
  • Radiation Therapy: Increased evidence supporting low-dose radiation therapy as a viable non-surgical option for early-stage disease (nodules, mild contractures <20°), particularly in preventing progression. Its role in recurrent disease is also being explored.
  • Molecular Research: Advances in understanding the molecular pathways (e.g., Wnt signaling, transforming growth factor-beta (TGF-β) pathway) involved in Dupuytren's fibrosis are opening doors for potential future targeted pharmacological therapies.
• Controversies:
  • Optimal Timing for Intervention: The precise threshold for intervention, especially for PIP joint contractures, remains debated.
  • Role of Post-Procedural Splinting: While commonly prescribed, the long-term efficacy of splinting in preventing recurrence, particularly after CCH or NA, is not definitively established by high-quality evidence.
  • Management of Recurrence: The optimal approach to recurrent disease (repeat NA, CCH, or surgery) is still a topic of active discussion and varies based on the pattern and severity of recurrence.
  • Cost-Effectiveness: Balancing the cost of newer, less invasive treatments (like CCH) against their effectiveness and recurrence rates compared to traditional surgery.

Key References

• Guidelines:
  • British Society for Surgery of the Hand (BSSH) guidelines for Dupuytren's Contracture management.
  • American Society for Surgery of the Hand (ASSH) position statements and clinical reviews on Dupuytren's disease.
• Studies:
  • CORD I, II, III Trials: Pivotal randomized controlled trials demonstrating the efficacy and safety of collagenase clostridium histolyticum (CCH) for Dupuytren's contracture.
  • Studies on Radiation Therapy: Numerous studies evaluating low-dose radiation for early-stage and recurrent Dupuytren's, e.g., published in International Journal of Radiation Oncology or Radiotherapy and Oncology.
  • Comparative Studies: Research comparing outcomes of needle aponeurotomy, collagenase injection, and various surgical techniques, found in journals such as The Journal of Hand Surgery (American and European volumes), Plastic and Reconstructive Surgery, Clinical Orthopaedics and Related Research.
• Reviews:
  • Comprehensive reviews available through clinical reference tools like UpToDate, OrthoEvidence, and major orthopedic and hand surgery textbooks.
  • Systematic reviews and meta-analyses published in high-impact medical journals.